期刊文献+

尿NAG联合血清β2-MG、Cys-C对多发性骨髓瘤患者肾功能损伤的预测价值 被引量:5

Predictive Value of Urinary NAG Combined with Serumβ2-MG and Cystatin C in Renal Function Damage of Patients with Multiple Myeloma
下载PDF
导出
摘要 目的探讨尿N-乙酰-β-氨基葡萄糖苷酶(n-acetyl-beta-d-glucosidase,NAG)联合血清β2-微球蛋白(β2-microglobulin,β2-MG)、胱抑素-C(cystatin-C,Cys-C)对多发性骨髓瘤(multiple myeloma,MM)患者肾功能损伤的预测价值。方法收集MM 116例,根据肾功能损伤情况将其分为肾功能损伤组(45例)和肾功能正常组(71例)两组。比较两组一般资料和实验室指标,采用Logistic回归分析对影响MM患者肾功能损伤的相关因素进行分析,采用受试者工作特征(ROC)曲线分析尿NAG联合血清β2-MG、Cys-C对MM患者肾功能损伤的预测价值。结果肾功能损伤组国际分期系统(international staging system,ISS)分期、尿NAG及血清β2-MG、Cys-C、肌酐(creatinine,Cr)高于肾功能正常组,血红蛋白低于肾功能正常组,差异均有统计学意义(P<0.05或P<0.01)。多因素Logistic回归分析结果显示,ISS分期Ⅲ期、尿NAG≥2.37 U/mmol及血清β2-MG≥6.3 mg/L、Cys-C≥0.98 mg/L、Cr≥135μmol/L为MM患者肾功能损伤的危险因素(P<0.05)。ROC曲线分析结果显示,尿NAG和血清β2-MG、Cys-C、Cr预测MM患者肾功能损伤的曲线下面积(AUC)依次为0.812、0.808、0.813和0.745;尿NAG联合血清β2-MG、Cys-C预测MM患者肾功能损伤的AUC为0.894。结论尿NAG联合血清β2-MG、Cys-C对MM患者肾功能损伤具有较高预测价值。 Objective To analyze the predictive value of urinary n-acetyl-beta-d-glucosidase(NAG)combined with serumβ2 microglobulin(β2-MG)and cystatin C(Cys-C)in evaluating renal function damage of patients with multiple myeloma(MM).Methods A total of 116 patients with MM were enrolled and divided into renal function damage group(n=45)and normal renal function group(n=71)according to their renal function damage.The general data and laboratory indicators of patients in two groups were compared.Logistic regression analysis was performed to analyze factors related to renal function damage in MM patients.ROC curve was performed to analyze predictive value of urine NAG,serumβ2-MG and Cys-C for renal function damage in MM patients.Results The international staging system(ISS)staging,urine NAG,serumβ2-MG,Cys-C and creatinine(Cr)in renal function damage group were higher than those in normal renal function group,while hemoglobin was lower than that in normal renal function group(P<0.05 or P<0.01).The results of multivariate Logistic regression analysis showed that ISS stageⅢ,urine NAG≥2.37 U/mmol,serumβ2-MG≥6.3 mg/L,Cys-c≥0.98 mg/L,and Cr≥135μmol/L were risk factors for renal function damage in MM patients(P<0.05).The results of ROC curve analysis showed that the AUC of urine NAG,serumβ2-MG,Cys-C and Cr for renal function in MM patients were 0.812,0.808,0.813,0.745,respectively.The AUC of NAG combined with serumβ2-MG and Cys-c for renal function in MM patients was 0.894.Conclusion Urine NAG combined with serumβ2-MG and Cys-c have higher predictive value for renal function damage in MM patients.
作者 刘芳 余艳丽 郭彩利 LIU Fang;YU Yan-li;GUO Cai-li(Department of Hematology,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710065,China)
出处 《临床误诊误治》 2020年第11期91-95,共5页 Clinical Misdiagnosis & Mistherapy
基金 陕西省重点研发计划项目(2019SF-163)。
关键词 多发性骨髓瘤 肾功能损伤 N-乙酰-Β-氨基葡萄糖苷酶 Β2微球蛋白 胱抑素C Multiple myeloma Renal function damage N-acetyl-lanyl-glucosaminosidase β2 microglobulin Cystatin C
  • 相关文献

参考文献13

二级参考文献130

  • 1刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93. 被引量:1218
  • 2邹操,刘志华,宋建平,杨向军,蒋廷波,高美雯,金建玲,蒋文平.24h平稳降压对高血压靶器官保护的临床意义[J].临床心血管病杂志,2005,21(3):155-157. 被引量:62
  • 3周振海,罗绍凯,李娟,李小银,李幼姬,洪文德.多发性骨髓瘤本周蛋白基因可变区特点与肾小管功能损害的关系[J].中华内科杂志,2005,44(9):677-680. 被引量:7
  • 4刘雪梅,徐金兰,周丽敏,刘丽秋,官旭华.多发性骨髓瘤肾功能不全的临床特征及危险因素分析[J].中华肿瘤防治杂志,2007,14(21):1609-1611. 被引量:9
  • 5Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma [J]. J Clin Onco], 2005, 23 ( 15 ): 3412-3420.
  • 6Dimopoulos MA, Kastritis E, Michalis E, et al. The International Scoring System (1SS) tbr multiple myeloma remains a robust prognostic tool independently of patients' renal function [J]. Ann Oncol, 2012, 23(3 ): 722-729.
  • 7Dimopoulos MA, Tcrpos E, Chanan-Khan A, et al. Renal impair- ment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group [J ]. J Clin Oncol, 2010, 28( 33 ):4976-4984.
  • 8Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma [Jl. Mayo Clin Proc, 2003, 78( 1 ): 21-33.
  • 9Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [ J ]. Leukemia, 2009, 23( 1 ): 3-9.
  • 10Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival [ J ]. Cancer, 1975, 36( 3 ): 842-854.

共引文献475

同被引文献59

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部